The European Lung Cancer Surgery Market size is expected to grow at a CAGR of 6.2% from 2023 to 2028. The value of the market is forecasted to grow USD 10.11 billion by 2028, from USD 7.48 billion in 2023.
Cancer is generally defined by the name of the part in which it starts. Lung Cancer is a Cancer that starts in Bronchus, lung Tissue, or Trachea. They are many ways to treat Lung Cancer like Radiotherapy, Chemotherapy, Laser therapy, and Surgery. Surgery involves the removal of the infected sections from the lungs. But Surgery can only be used if cancer cells don’t spread very near to the heart.
Rising pollution levels, an increasing number of cigarette smokers, rising incidence and prevalence of Lung Cancer, and rising geriatric population are major factors driving the market.
However, the high cost of Lung Cancer surgery is restraining the growth of the market.
This research report on the European Lung Cancer Surgery Market has been segmented & sub-segmented into the following categories:
Based on procedure, Minimally Invasive surgeries are expected to grow at the highest CAGR owing to the rising awareness among people for early detection of lung cancer and the advantages of Minimally Invasive Surgeries over conventional surgeries.
Based on the device, the Surgical Instruments segment is expected to dominate the market due to the shorter lifespan of devices and the wider adoption of these devices.
Geographically, Europe has the second-largest market after North America owing to its Advanced Healthcare facilities and higher awareness among people, and greater economic stability.
Promising companies leading the European Lung Cancer Surgery Market include Ethicon US LLC, Intuitive Surgical Inc., AngioDynamics Inc., Olympus Corporation, Accuray Inc., Ackermann Instrumente GmbH, Teleflex Inc., KARL STORZ GmbH, Scanlan International Inc., and Trokamed GmbH.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]